Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

MC #22-33

Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid Tumors

NCT #
NCT05579366
Condition(s)
Breast, Endometrial, Mesothelioma, Non-Small Cell Lung, Ovarian, triple negative Breast
Molecular Target(s)
FRĪ±
Drug Classification(s)
Antibody Drug Conjugate
Agents(s)
PRO1184
Phase(s)
I/II

Mechanism of Action

PRO1184 is an antibody drug conjugate that is directed to folate molecules to bind to cells with folate receptor in order to deliver the attached cytotoxic payload molecules

Purpose

  • How much of the study agent can be given with an acceptable level of side effects
  • The effects of the study agent (good and bad)
  • How much of the study agent is absorbed into the blood and how fast it is removed
  • If research tests can be used in the future to predict who will benefit from PRO1184
  • How the study agent is acting on your body

Location

MCD

Connect With Us

Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.